Bromodomain and extra-terminal inhibitors—A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children—ACCELERATE

Based on biology and pre-clinical data, bromodomain and extra-terminal (BET) inhibitors have at least three potential roles in paediatric malignancies: NUT (nuclear protein in testis) carcinomas, MYC/MYCN-driven cancers and fusion-driven malignancies. However, there are now at least 10 BET inhibitor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2021-03, Vol.146 (3), p.115-124
Hauptverfasser:	Pearson, Andrew DJ, DuBois, Steven G., Buenger, Vickie, Kieran, Mark, Stegmaier, Kimberly, Bandopadhayay, Pratiti, Bennett, Kelly, Bourdeaut, Franck, Brown, Patrick A., Chesler, Louis, Clymer, Jessica, Fox, Elizabeth, French, Christopher A., Germovsek, Eva, Giles, Francis J., Bender, Julia G., Hattersley, Maureen M., Ludwinski, Donna, Luptakova, Katarina, Maris, John, McDonough, Joe, Nikolova, Zariana, Smith, Malcolm, Tsiatis, Athanasios C., Vibhakar, Rajeev, Weiner, Susan, Yi, Joanna S., Zheng, Fred, Vassal, Gilles
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescents Adults Anticancer properties Antineoplastic Agents - therapeutic use BET inhibitors Biopharmaceuticals Bromodomain Cancer Cancer therapeutics Carcinoma Central nervous system Child Children Clinical trials Consensus Correlation analysis Drug development Drug Development - methods Epigenesis, Genetic Epigenetic mechanisms Epigenetics Humans Inhibitors Life Sciences Malignancy Molecular Targeted Therapy Myc protein MYC/MYCN Neoplasms - drug therapy Neoplasms - metabolism Neoplasms - pathology NUT Paediatric oncology Paediatric Strategy Forum Pediatrics Product development Proteins - antagonists & inhibitors Thrombocytopenia Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!